Skip to main content

kras g12d inhibitor incb161734

Generic: KRAS G12D Inhibitor INCB161734

kras g12d inhibitor incb161734: 3 clinical trials tracked.

kras g12d inhibitor incb161734 evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about kras g12d inhibitor incb161734, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trials (3)

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

NCT07522073·Phase 3·INCY
Recruiting

Primary endpoint: Overall Survival (OS)

InterventionalRandomizeddouble588 targetStarted 2026-04Completion 2029-0350 sites · United StatesIncyte Corporation

An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

NCT07018635·Phase 1·INCY
Completed

Primary endpoint: Pharmacokinetics Parameter (PK): Cmax of INCB161734

Interventionalopen63 enrolledStarted 2025-07Completion 2025-091 site · United StatesIncyte Corporation

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160·Phase 1·INCY
Recruiting

Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)

Interventionalopen710 targetStarted 2024-01Completion 2027-0134 sites · Australia, Belgium, Canada, France…Incyte Corporation